The intravenous drug deactivates the uterine sensitization-associated gene-1 (USAG-1) protein that suppresses tooth growth, triggering bone growth and regrowing teeth.
Human trials starting in September show confidence in the drug's success, supported by past positive outcomes in treating animals, aiming to make the drug available by 2030.
[
add
]
[
|
|
...
]